Media coverage about Seattle Genetics (NASDAQ:SGEN) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Seattle Genetics earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.5922316898623 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have effected Accern’s analysis:

SGEN has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and set a $72.00 target price on shares of Seattle Genetics in a research report on Tuesday, June 20th. Jefferies Group LLC reissued a “buy” rating and set a $53.00 target price on shares of Seattle Genetics in a research report on Thursday, July 27th. TheStreet cut shares of Seattle Genetics from a “c-” rating to a “d” rating in a research report on Tuesday, May 9th. Cantor Fitzgerald set a $43.00 target price on shares of Seattle Genetics and gave the company a “hold” rating in a research report on Monday, June 19th. Finally, Cowen and Company reissued a “hold” rating and set a $54.00 target price (down previously from $61.00) on shares of Seattle Genetics in a research report on Monday, June 19th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Seattle Genetics currently has an average rating of “Hold” and a consensus target price of $62.29.

Seattle Genetics (NASDAQ SGEN) opened at 52.55 on Friday. The stock’s market cap is $7.52 billion. Seattle Genetics has a 12-month low of $44.45 and a 12-month high of $75.36. The firm has a 50 day moving average of $49.99 and a 200-day moving average of $59.90.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.03. Seattle Genetics had a negative net margin of 47.38% and a negative return on equity of 32.87%. The firm had revenue of $108.20 million during the quarter, compared to the consensus estimate of $105.92 million. During the same quarter in the prior year, the firm earned ($0.23) EPS. Seattle Genetics’s revenue for the quarter was up 13.4% on a year-over-year basis. On average, analysts expect that Seattle Genetics will post ($1.69) earnings per share for the current year.

In related news, insider Vaughn B. Himes sold 6,377 shares of the company’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $47.89, for a total value of $305,394.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Jonathan G. Drachman sold 10,000 shares of the company’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $47.54, for a total transaction of $475,400.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 119,712 shares of company stock valued at $6,198,785. 34.70% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/02/seattle-genetics-sgen-given-daily-coverage-optimism-rating-of-0-18.html.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Stock Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related stocks with our FREE daily email newsletter.